Zydus Cadila has introduced a breast cancer drug in India, a copy of Swiss giant Roche’s product Herceptin. The company selling a version of trastuzumab in the country under the brand Vivitra. A government expert committee had approved Vivitra in October after recommending certain changes to the product information provided in the package. Each vial of Vivitra is priced at Rs 64,999, according to the product label reviewed by ET. Officials in the trade indicated the drug will be discounted to match competition.
Company Profile : Cadila Healthcare Ltd
Leave a Reply